Fast. Effective. Safe.
Acute myocardial infarction (AMI) may safely be ruled out by testing a single blood sample at patient presentation. In a recently-completed intervention study, using a Copeptin-based diagnostic algorithm enabled immediate discharge of 2/3 of patients with suspected acute coronary syndrome (ACS) from the emergency department. At 30 days, patients managed using Copeptin had 100% survival and a comparably low major cardiovascular event rate (MACE) to that in patients undergoing conventional multiple laboratory testing and hours-long observation. Based on these results, the Thermo Scientific™ B•R•A•H•M•S™ Copeptin biomarker assays improve patient care and clinical resource allocation - without compromising safety.
The publication of this interview was supported by Thermo Fisher Scientific.
An interview with Professor Bertil Lindahl, Uppsala Clinical Research Centre, Uppsala University, Sweden